Macerich Company (The) Common Stock vs 22nd Century Group Inc — how do they compare? Macerich Company (The) Common Stock trades at $22.18 (market cap $6.29B), while 22nd Century Group Inc trades at $0.65 (market cap $464.52K). The key difference: Macerich Company (The) Common Stock is far larger — about 13540.9× 22nd Century Group Inc's market cap, and Macerich Company (The) Common Stock pays a 3.07% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Macerich Company (The) Common Stock for 0 Days and 22nd Century Group Inc for 33 Days on average.
| MAC | XXII | |
|---|---|---|
Market Cap | $6.29B | $464.52K |
Volume | 3,158,142 | 16,668 |
Sector | Real Estate | Consumer Staples |
52-Week High | $26.51 | $483.00 |
52-Week Low | $16.20 | $0.65 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $10.97B | -$3.84M |
Dividend Yield | 3.07% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XXII trades at $0.67, down 7.98% in the last session, with a bearish technical signal from moving averages. The company shows negative profitability metrics including -76.01% net income margin and -284.5% ROE, though valuation ratios appear low with P/S of 0.06 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives in France and Europe.
Despite analyst optimism (75% buy ratings with $1,240 price target), fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock faces significant execution risk in commercializing reduced-nicotine tobacco products while navigating regulatory timelines.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The Macerich Company is a real estate investment trust that owns, operates, and redevelops shopping centers concentrated in California, the Pacific Northwest, and other major US markets.
Read more on MAC →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →